Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

Catherine Labbé, Michael Cabanero, Grzegorz Korpanty, +14

Lung Cancer

MedicinePathologyCancer GenomicsBronchial NeoplasmCancer Genetics +5

Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study

Fiona Blackhall, Kevin Jao, Laurent Greillier, +21

Journal of Thoracic Oncology

High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study

Arielle Elkrief, Antoine Desîlets, Neha Papneja, +20

European Journal of Cancer

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

Antoine Desîlets, Félix Blanc‐Durand, Sally C. M. Lau, +27

European Journal of Cancer

Real-world Multicentre StudyMedicineHistorical CohortMetronomic TherapyBronchial Neoplasm +7

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

Neal Ready, Clarisse Audigier-Valette, Jonathan W. Goldman, +25

Journal for ImmunoTherapy of Cancer

Treatment options for patients with brain metastases from EGFR / ALK -driven lung cancer

Mark Doherty, Grzegorz Korpanty, Pascale Tomasini, +14

Radiotherapy and Oncology

Neuro-oncologyHealth SciencesBrain MetastasesMedicineBronchial Neoplasm +6

OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

Fabrice Barlési, Clarisse Audigier-Valette, Enriqueta Felip, +21

Journal of Thoracic Oncology

Advanced NsclcEcog Ps 2Therapeutic EfficacyPharmacotherapyMedicine +2

The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer

Kevin Jao, Pascale Tomasini, Suzanne Kamel‐Reid, +12

Lung Cancer

Somatic VariantTumor HeterogeneityMedicinePathologyCancer Genomics +9

Central Nervous System Pseudoprogression in a Patient Treated with PD-1 Checkpoint Inhibitor

Mark Doherty, Kevin Jao, Frances A. Shepherd, +2

Journal of Thoracic Oncology

Neuro-oncologyPd-1 Checkpoint InhibitorMedicinePathologyImmune Checkpoint Inhibitor +4

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non–small-cell Lung Cancer

Pascale Tomasini, Céline Mascaux, Kevin Jao, +10

Clinical Lung Cancer

Coexisting KrasNon–small-cell Lung CancerMedicinePathologyCancer Cell Biology +7